41 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
21700453	56	Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.	Msd
21458261	55	The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.	Msd
7752199	71	Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.	Medical College Of Ohio
19800231	92	Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.	Schering-Plough Research Institute
17300166	88	Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.	University Of Montpellier
16297621	17	Pyridobenzodiazepines: a novel class of orally active, vasopressin V2 receptor selective agonists.	Wyeth Research
15857144	10	Design of benzophenone-containing photoactivatable linear vasopressin antagonists: pharmacological and photoreactive properties.	University Of Montpellier
1331448	101	Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product.	Merck Research Laboratories
1732523	46	Preparation and biological activities of potential vasopressin photoaffinity labels.	University Of Sherbrooke
15149662	71	Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.	Johnson And Johnson Pharmaceutical Research And Development
11755361	24	N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.	Yamanouchi Pharmaceutical
10201826	24	Synthesis of oxytocin antagonists containing conformationally constrained amino acids in position 2.	Albert Szent-Gy£Rgyi Medical University
21688787	295	New, potent, selective, and short-acting peptidic V1a receptor agonists.	Ferring Research Institute
20550119	96	Oral oxytocin antagonists.	Drugmoldesign
7807119	5	Khusimol, a Non-Peptide Ligand for Vasopressin V1a Receptors	TBA
	4	Vasopressin trisulphide: synthesis, NMR study and affinity studies with V1 and V2 subtypes receptors	TBA
	66	Non-peptide oxytocin antagonists: identification and synthesis of a potent camphor aminosuccinimide	TBA
17942308	62	Next-generation spirobenzazepines: identification of RWJ-676070 as a balanced vasopressin V1a/V2 receptor antagonist for human clinical studies.	Johnson & Johnson Pharmaceutical Research & Development
14695824	68	Synthesis and structure-activity relationships of 5,6,7,8-tetrahydro-4H-thieno[3,2-b]azepine derivatives: novel arginine vasopressin antagonists.	Central Pharmaceutical Research Institute
12798333	56	Structure-activity study of novel tricyclic benzazepine arginine vasopressin antagonists.	Wyeth Research
12036368	59	Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.	Yamanouchi Pharmaceutical
11087564	30	Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.	Otsuka Pharmaceutical
10782666	46	The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.	Wyeth-Ayerst Research
10406633	32	5-fluoro-2-methyl-N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-yl carbonyl)-2-pyridinyl]benzamide (CL-385004) and analogs as orally active arginine vasopressin receptor antagonists.	Wyeth-Ayerst Research
10406632	11	4,10-dihydro-5H-thieno[3,2-c][1]benzazepine derivatives and 9,10-dihydro-4H-thieno[2,3-c][1]benzazepine derivatives as orally active arginine vasopressin receptor antagonists.	Wyeth-Ayerst Research
10340620	30	Nonpeptide oxytocin antagonists: analogs of L-371,257 with improved potency.	Merck Research Laboratories
9651149	54	5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1, 4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors.	Wyeth-Ayerst Research
8784453	134	Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.	Otsuka Pharmaceutical
8393113	114	Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.	Otsuka Pharmaceutical
8258821	491	Nanomolar-affinity, non-peptide oxytocin receptor antagonists.	Merck Research Laboratories
8126695	35	1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.	Merck Research Laboratories
8021923	27	A new series of photoactivatable and iodinatable linear vasopressin antagonists.	Upr 9023 Cnrs
7473590	37	1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.	Merck Research Laboratories
2416923	40	Arginine-vasopressin analogues with high antidiuretic/vasopressor selectivity. Synthesis, biological activity, and receptor binding affinity of arginine-vasopressin analogues with substitutions in positions 1, 2, 4, 7, and 8.	TBA
2163451	45	Cyclic hexapeptide oxytocin antagonists. Potency-, selectivity-, and solubility-enhancing modifications.	Merck Sharp & Dohme Research Laboratories
1331449	268	Orally active, nonpeptide oxytocin antagonists.	Merck Research Laboratories